# Anti PD-1 Neo-adjuvant Treatment for NSCLC

> **NCT02938624** · PHASE1 · COMPLETED · sponsor: **Jair Bar, M.D., Ph.D.** · enrollment: 28 (actual)

## Conditions studied

- Non Small Cell Lung Carcinoma
- Stage I
- Stage II

## Interventions

- **DRUG:** Pembrolizumab 200 mg IV single dose
- **DRUG:** Pembrolizumab 200 mg IV twice interval 21 days
- **DRUG:** Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
- **DRUG:** Pembrolizumab 100 mg I.V single dose
- **PROCEDURE:** Surgical resection of tumor

## Key facts

- **NCT ID:** NCT02938624
- **Lead sponsor:** Jair Bar, M.D., Ph.D.
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-07
- **Primary completion:** 2021-08
- **Final completion:** 2021-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938624, "Anti PD-1 Neo-adjuvant Treatment for NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02938624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*